Loading…
Insight into the current practice of ototoxicity monitoring during cisplatin therapy
The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines. Case series including retrospective medical rec...
Saved in:
| Published in: | Journal of otolaryngology 2021-03, Vol.50 (1), p.19-19 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3 |
| container_end_page | 19 |
| container_issue | 1 |
| container_start_page | 19 |
| container_title | Journal of otolaryngology |
| container_volume | 50 |
| creator | Santucci, N M Garber, B Ivory, R Kuhn, M A Stephen, M Aizenberg, D |
| description | The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines.
Case series including retrospective medical records review of patients (age > 18) treated with cisplatin at University of California Davis Medical Center between January 2014 and August 2017. Patient and ototoxicity related variables were analyzed. Patients that underwent a transfer of care during treatment and with less than 3 months of follow-up were excluded.
Three hundred seventy-nine patients met study criteria, of which 104 (27.4%) had a prior history of hearing loss. Prior to treatment, 196 (51.7%) patients were counseled regarding the ototoxic nature of cisplatin and 92 (24.3%) patients had a pretreatment audiogram. During treatment, 91 (24%) patients had documented otologic complaints. Only 17 patients (4.5%) patients had an audiogram ordered during their cisplatin treatment period. 130 (34.3%) patients had otologic complaints following cisplatin treatment. Audiograms were ordered for 20 (7.8%), 13 (5.1%), and 16 (6.2%) patients at 1-month, 3-month, and 6-month follow-ups, respectively. No patients in the study cohort received baseline, treatment, and post-treatment audiograms as recommended by national ototoxicity monitoring protocols. Patients with Head and Neck Cancer (HNC) represented the largest subgroup that received cisplatin (n = 122, 32.2%) and demonstrated higher rates of ototoxicity counseling (n = 103, 84.4%) and pretreatment audiograms (n = 70, 57.4%) compared to the non HNC group (n = 36, 36.2%, P |
| doi_str_mv | 10.1186/s40463-021-00506-0 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_00760dd2ed374c1581ed4b36abeffc27</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A657287982</galeid><doaj_id>oai_doaj_org_article_00760dd2ed374c1581ed4b36abeffc27</doaj_id><sourcerecordid>A657287982</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3</originalsourceid><addsrcrecordid>eNptUl2L1DAULaK46-of8EEKgvjS9SZtk-ZFWBY_BhZ8WZ9Dmo82Q5vUJBXn35uZWdcZkTzccHLOSe7NKYrXCK4R6siH2EBD6gowqgBaIBU8KS4RQ2QPkacn-4viRYxbANK0CJ4XF3VNCUENvizuNy7aYUyldcmXadSlXEPQLpVLEDJZqUtvSp_y-mWlTbty9s4mH6wbSrUeirRxmUSybq8PYtm9LJ4ZMUX96qFeFd8_f7q__Vrdffuyub25q2TLmlS1VOYHQQed6RUmnaCt7EXbYGC9JoYpoTGAUhkigtYKMwUNUr1RYJiQsr4qNkdf5cWWL8HOIuy4F5YfAB8GLkLuYdIcgJJshbWqaSNR2yGtmr4motfGSEyz18ej17L2s1YyjyCI6cz0_MTZkQ_-J6eMtRRQNnj_YBD8j1XHxGcbpZ4m4bRfI8f5hzBlmLBMffsPdevX4PKoMgs1FJMa4b-sQeQGrDM-3yv3pvyGtBR3lHV71vV_WHkpPVvpnTY242eCdyeCUYspjdFPa7LexXMiPhJl8DEGbR6HgYDvA8iPAeQ5YfwQQA5Z9OZ0jI-SP4mrfwNYyNYk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2514726312</pqid></control><display><type>article</type><title>Insight into the current practice of ototoxicity monitoring during cisplatin therapy</title><source>SAGE Open Access</source><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><creator>Santucci, N M ; Garber, B ; Ivory, R ; Kuhn, M A ; Stephen, M ; Aizenberg, D</creator><creatorcontrib>Santucci, N M ; Garber, B ; Ivory, R ; Kuhn, M A ; Stephen, M ; Aizenberg, D</creatorcontrib><description>The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines.
Case series including retrospective medical records review of patients (age > 18) treated with cisplatin at University of California Davis Medical Center between January 2014 and August 2017. Patient and ototoxicity related variables were analyzed. Patients that underwent a transfer of care during treatment and with less than 3 months of follow-up were excluded.
Three hundred seventy-nine patients met study criteria, of which 104 (27.4%) had a prior history of hearing loss. Prior to treatment, 196 (51.7%) patients were counseled regarding the ototoxic nature of cisplatin and 92 (24.3%) patients had a pretreatment audiogram. During treatment, 91 (24%) patients had documented otologic complaints. Only 17 patients (4.5%) patients had an audiogram ordered during their cisplatin treatment period. 130 (34.3%) patients had otologic complaints following cisplatin treatment. Audiograms were ordered for 20 (7.8%), 13 (5.1%), and 16 (6.2%) patients at 1-month, 3-month, and 6-month follow-ups, respectively. No patients in the study cohort received baseline, treatment, and post-treatment audiograms as recommended by national ototoxicity monitoring protocols. Patients with Head and Neck Cancer (HNC) represented the largest subgroup that received cisplatin (n = 122, 32.2%) and demonstrated higher rates of ototoxicity counseling (n = 103, 84.4%) and pretreatment audiograms (n = 70, 57.4%) compared to the non HNC group (n = 36, 36.2%, P < 0.0001 and n = 22, 8.5%, P < 0.0001).
There is poor adherence to national ototoxicity monitoring guidelines at a large academic medical center. This is a missed opportunity for intervention and aural rehabilitation. Improved education and collaboration between otolaryngology, audiology, and medical oncology is needed to develop and promote an effective ototoxicity-monitoring program.</description><identifier>ISSN: 1916-0216</identifier><identifier>ISSN: 1916-0208</identifier><identifier>EISSN: 1916-0216</identifier><identifier>DOI: 10.1186/s40463-021-00506-0</identifier><identifier>PMID: 33766142</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antimitotic agents ; Antineoplastic agents ; Audiogram ; Audiologic ; Audiology ; Cancer ; Cancer therapies ; Chemotherapy ; Cisplatin ; Counseling ; Drug dosages ; Hair ; Hearing loss ; Medical centers ; Medical colleges ; Medical records ; Medical research ; Medicine, Experimental ; Original ; Otolaryngology ; Otologic ; Otology ; Ototoxicity ; Patients ; Quality control ; Quality of life ; Terminology ; Tinnitus</subject><ispartof>Journal of otolaryngology, 2021-03, Vol.50 (1), p.19-19</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3</citedby><cites>FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995701/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995701/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33766142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Santucci, N M</creatorcontrib><creatorcontrib>Garber, B</creatorcontrib><creatorcontrib>Ivory, R</creatorcontrib><creatorcontrib>Kuhn, M A</creatorcontrib><creatorcontrib>Stephen, M</creatorcontrib><creatorcontrib>Aizenberg, D</creatorcontrib><title>Insight into the current practice of ototoxicity monitoring during cisplatin therapy</title><title>Journal of otolaryngology</title><addtitle>J Otolaryngol Head Neck Surg</addtitle><description>The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines.
Case series including retrospective medical records review of patients (age > 18) treated with cisplatin at University of California Davis Medical Center between January 2014 and August 2017. Patient and ototoxicity related variables were analyzed. Patients that underwent a transfer of care during treatment and with less than 3 months of follow-up were excluded.
Three hundred seventy-nine patients met study criteria, of which 104 (27.4%) had a prior history of hearing loss. Prior to treatment, 196 (51.7%) patients were counseled regarding the ototoxic nature of cisplatin and 92 (24.3%) patients had a pretreatment audiogram. During treatment, 91 (24%) patients had documented otologic complaints. Only 17 patients (4.5%) patients had an audiogram ordered during their cisplatin treatment period. 130 (34.3%) patients had otologic complaints following cisplatin treatment. Audiograms were ordered for 20 (7.8%), 13 (5.1%), and 16 (6.2%) patients at 1-month, 3-month, and 6-month follow-ups, respectively. No patients in the study cohort received baseline, treatment, and post-treatment audiograms as recommended by national ototoxicity monitoring protocols. Patients with Head and Neck Cancer (HNC) represented the largest subgroup that received cisplatin (n = 122, 32.2%) and demonstrated higher rates of ototoxicity counseling (n = 103, 84.4%) and pretreatment audiograms (n = 70, 57.4%) compared to the non HNC group (n = 36, 36.2%, P < 0.0001 and n = 22, 8.5%, P < 0.0001).
There is poor adherence to national ototoxicity monitoring guidelines at a large academic medical center. This is a missed opportunity for intervention and aural rehabilitation. Improved education and collaboration between otolaryngology, audiology, and medical oncology is needed to develop and promote an effective ototoxicity-monitoring program.</description><subject>Analysis</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Audiogram</subject><subject>Audiologic</subject><subject>Audiology</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Counseling</subject><subject>Drug dosages</subject><subject>Hair</subject><subject>Hearing loss</subject><subject>Medical centers</subject><subject>Medical colleges</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Original</subject><subject>Otolaryngology</subject><subject>Otologic</subject><subject>Otology</subject><subject>Ototoxicity</subject><subject>Patients</subject><subject>Quality control</subject><subject>Quality of life</subject><subject>Terminology</subject><subject>Tinnitus</subject><issn>1916-0216</issn><issn>1916-0208</issn><issn>1916-0216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUl2L1DAULaK46-of8EEKgvjS9SZtk-ZFWBY_BhZ8WZ9Dmo82Q5vUJBXn35uZWdcZkTzccHLOSe7NKYrXCK4R6siH2EBD6gowqgBaIBU8KS4RQ2QPkacn-4viRYxbANK0CJ4XF3VNCUENvizuNy7aYUyldcmXadSlXEPQLpVLEDJZqUtvSp_y-mWlTbty9s4mH6wbSrUeirRxmUSybq8PYtm9LJ4ZMUX96qFeFd8_f7q__Vrdffuyub25q2TLmlS1VOYHQQed6RUmnaCt7EXbYGC9JoYpoTGAUhkigtYKMwUNUr1RYJiQsr4qNkdf5cWWL8HOIuy4F5YfAB8GLkLuYdIcgJJshbWqaSNR2yGtmr4motfGSEyz18ej17L2s1YyjyCI6cz0_MTZkQ_-J6eMtRRQNnj_YBD8j1XHxGcbpZ4m4bRfI8f5hzBlmLBMffsPdevX4PKoMgs1FJMa4b-sQeQGrDM-3yv3pvyGtBR3lHV71vV_WHkpPVvpnTY242eCdyeCUYspjdFPa7LexXMiPhJl8DEGbR6HgYDvA8iPAeQ5YfwQQA5Z9OZ0jI-SP4mrfwNYyNYk</recordid><startdate>20210325</startdate><enddate>20210325</enddate><creator>Santucci, N M</creator><creator>Garber, B</creator><creator>Ivory, R</creator><creator>Kuhn, M A</creator><creator>Stephen, M</creator><creator>Aizenberg, D</creator><general>BioMed Central Ltd</general><general>Sage Publications Ltd</general><general>BioMed Central</general><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M3G</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210325</creationdate><title>Insight into the current practice of ototoxicity monitoring during cisplatin therapy</title><author>Santucci, N M ; Garber, B ; Ivory, R ; Kuhn, M A ; Stephen, M ; Aizenberg, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Audiogram</topic><topic>Audiologic</topic><topic>Audiology</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Counseling</topic><topic>Drug dosages</topic><topic>Hair</topic><topic>Hearing loss</topic><topic>Medical centers</topic><topic>Medical colleges</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Original</topic><topic>Otolaryngology</topic><topic>Otologic</topic><topic>Otology</topic><topic>Ototoxicity</topic><topic>Patients</topic><topic>Quality control</topic><topic>Quality of life</topic><topic>Terminology</topic><topic>Tinnitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santucci, N M</creatorcontrib><creatorcontrib>Garber, B</creatorcontrib><creatorcontrib>Ivory, R</creatorcontrib><creatorcontrib>Kuhn, M A</creatorcontrib><creatorcontrib>Stephen, M</creatorcontrib><creatorcontrib>Aizenberg, D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>CBCA Reference & Current Events</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of otolaryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santucci, N M</au><au>Garber, B</au><au>Ivory, R</au><au>Kuhn, M A</au><au>Stephen, M</au><au>Aizenberg, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insight into the current practice of ototoxicity monitoring during cisplatin therapy</atitle><jtitle>Journal of otolaryngology</jtitle><addtitle>J Otolaryngol Head Neck Surg</addtitle><date>2021-03-25</date><risdate>2021</risdate><volume>50</volume><issue>1</issue><spage>19</spage><epage>19</epage><pages>19-19</pages><issn>1916-0216</issn><issn>1916-0208</issn><eissn>1916-0216</eissn><abstract>The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines.
Case series including retrospective medical records review of patients (age > 18) treated with cisplatin at University of California Davis Medical Center between January 2014 and August 2017. Patient and ototoxicity related variables were analyzed. Patients that underwent a transfer of care during treatment and with less than 3 months of follow-up were excluded.
Three hundred seventy-nine patients met study criteria, of which 104 (27.4%) had a prior history of hearing loss. Prior to treatment, 196 (51.7%) patients were counseled regarding the ototoxic nature of cisplatin and 92 (24.3%) patients had a pretreatment audiogram. During treatment, 91 (24%) patients had documented otologic complaints. Only 17 patients (4.5%) patients had an audiogram ordered during their cisplatin treatment period. 130 (34.3%) patients had otologic complaints following cisplatin treatment. Audiograms were ordered for 20 (7.8%), 13 (5.1%), and 16 (6.2%) patients at 1-month, 3-month, and 6-month follow-ups, respectively. No patients in the study cohort received baseline, treatment, and post-treatment audiograms as recommended by national ototoxicity monitoring protocols. Patients with Head and Neck Cancer (HNC) represented the largest subgroup that received cisplatin (n = 122, 32.2%) and demonstrated higher rates of ototoxicity counseling (n = 103, 84.4%) and pretreatment audiograms (n = 70, 57.4%) compared to the non HNC group (n = 36, 36.2%, P < 0.0001 and n = 22, 8.5%, P < 0.0001).
There is poor adherence to national ototoxicity monitoring guidelines at a large academic medical center. This is a missed opportunity for intervention and aural rehabilitation. Improved education and collaboration between otolaryngology, audiology, and medical oncology is needed to develop and promote an effective ototoxicity-monitoring program.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33766142</pmid><doi>10.1186/s40463-021-00506-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1916-0216 |
| ispartof | Journal of otolaryngology, 2021-03, Vol.50 (1), p.19-19 |
| issn | 1916-0216 1916-0208 1916-0216 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_00760dd2ed374c1581ed4b36abeffc27 |
| source | SAGE Open Access; ProQuest - Publicly Available Content Database; PubMed Central |
| subjects | Analysis Antimitotic agents Antineoplastic agents Audiogram Audiologic Audiology Cancer Cancer therapies Chemotherapy Cisplatin Counseling Drug dosages Hair Hearing loss Medical centers Medical colleges Medical records Medical research Medicine, Experimental Original Otolaryngology Otologic Otology Ototoxicity Patients Quality control Quality of life Terminology Tinnitus |
| title | Insight into the current practice of ototoxicity monitoring during cisplatin therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A15%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insight%20into%20the%20current%20practice%20of%20ototoxicity%20monitoring%20during%20cisplatin%20therapy&rft.jtitle=Journal%20of%20otolaryngology&rft.au=Santucci,%20N%20M&rft.date=2021-03-25&rft.volume=50&rft.issue=1&rft.spage=19&rft.epage=19&rft.pages=19-19&rft.issn=1916-0216&rft.eissn=1916-0216&rft_id=info:doi/10.1186/s40463-021-00506-0&rft_dat=%3Cgale_doaj_%3EA657287982%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c594t-57c6450808fbd268a75cba54209be6f9dae200dda546a73d29d041dbfd0f9acc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2514726312&rft_id=info:pmid/33766142&rft_galeid=A657287982&rfr_iscdi=true |